Literature DB >> 25086164

Nocturnal enuresis: an approach to assessment and treatment.

Aaron P Bayne1, Steven J Skoog1.   

Abstract

On the basis of strong evidence, although primary monosymptomatic nocturnal enuresis (PMNE) is common and most children will outgrow the condition spontaneously, the psychological effect to the child can be significant and represents the main reason for treatment of these children. On the basis of international consensus panels, treatment of PMNE should be targeted toward the specific type of bedwetting patterns the child has, using bladder diary, sleep history, and daytime elimination concerns as a guide (Table 3). On the basis of international consensus panels, it is important for the primary care physician to be able to differentiate children with PMNE from children with nonmonosymptomatic nocturnal enuresis (NMNE) and secondary nocturnal enuresis. On the basis of international consensus panels, children with NMNE should have their underlying voiding or stool problem addressed before initiation of therapy for the nocturnal enuresis. On the basis of strong evidence, both the bedwetting alarm and desmopressin are considered first-line therapy for children with PMNE.

Entities:  

Mesh:

Year:  2014        PMID: 25086164     DOI: 10.1542/pir.35-8-327

Source DB:  PubMed          Journal:  Pediatr Rev        ISSN: 0191-9601


  3 in total

1.  Monosymptomatic Nocturnal Enuresis Treatment Using Alarm-Therapy and Desmopressin: A Meta-analysis Approach.

Authors:  Athaya Febriantyo Purnomo; Besut Daryanto; Pradana Nurhadi
Journal:  Med Arch       Date:  2021-12

2.  Desmopressin plus anticholinergic agent in the treatment of nocturnal enuresis: A meta-analysis.

Authors:  Jianyong Yu; Zhaojun Yan; Shiying Zhou; Feng Han; Feng Xiao; Jian Han; Congling Sun
Journal:  Exp Ther Med       Date:  2017-08-07       Impact factor: 2.447

3.  A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial.

Authors:  Parvin Mousavi Ghanavati; Dinyar Khazaeli; Mohammadreza Amjadzadeh
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.